GT200000194A - COMBINATION CHEMOTHERAPY. - Google Patents
COMBINATION CHEMOTHERAPY.Info
- Publication number
- GT200000194A GT200000194A GT200000194A GT200000194A GT200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A
- Authority
- GT
- Guatemala
- Prior art keywords
- agents
- combination
- carboplatin
- paclitaxel
- compartment
- Prior art date
Links
- 238000009096 combination chemotherapy Methods 0.000 title 1
- 190000008236 CARBOPLATIN Chemical compound 0.000 abstract 4
- 229960004562 carboplatin Drugs 0.000 abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 3
- 229960001592 paclitaxel Drugs 0.000 abstract 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA INVENCION SE REFIERE A UN METODO PARA TRATAR TUMORES SOLIDOS AVANZADOS UTILIZANDO COMBINACIONES DE AGENTES ONCOLITICOS CONOCIDOS. EL USO DE LOS AGENTES JUNTOS PROPORCIONA INESPERADAMENTE UN EFICACIA MAYOR QUE SI SE EMPLEAN COMO AGENTES SIMPLES SOLAMENTE. HEMOS DESCUBIERTO UNA UNICA COMBINACION DE AGENTES ONCOLITICOS CONOCIDOS QUE EXHIBE UNA IMPORTANTE EFECTO SINERGETICO. LA COMBINACION UTILIZA EL AGENTE ACETILDINALINA, JUNTO CON PACLITAXEL Y/O CARBOPLATINA, EN UNA COMBINACION BINARIA O CON LOS TRES COMPONENTES SIMULTANEAMENTE. LA INVENCION COMPRENDE ADEMAS FORMULACIONES FARMACOLOGICAMENTE EFECTIVAS, TRATAMIENTOS, ADEMAS DE LA PRESENTACION EN UN COMPARTIMIENTO DE DOSIFICACION DE ACETIDINALINA Y EN OTRO COMPARTIMIENTO UNA DOSIFICACION DE CARBOPLATINA Y/O OTRO COMPARTIMIENTO DE DOSIFICACION DE PACLITAXEL. UNA COMBINACION DE AGENTES ANTINEOPLASICOS QUE COMPRENDEN UNA CANTIDAD ANTITUMOR DE ACETIDINALINA Y UNA CANTIDAD ANTITUMOR DE PACLITAXEL Y / O CARBOPLATINA. LA ACETILDINALINA EN COMBINACION CON PACLITAXEL Y / O CARBOPLATINA ES SINERGISTICA PARA TRATAR EL CANCER.THE INVENTION REFERS TO A METHOD FOR TREATING ADVANCED SOLID TUMORS USING COMBINATIONS OF KNOWN ONCOLITIC AGENTS. THE USE OF THE AGENTS TOGETHER PROVIDES UNFORGETTABLELY EFFECTIVENESS THAN IF USED AS SIMPLE AGENTS ONLY. WE HAVE DISCOVERED A UNIQUE COMBINATION OF KNOWN ONCOLITIC AGENTS THAT DISPLAYS AN IMPORTANT SYNERGETIC EFFECT. THE COMBINATION USES THE ACETILDINAL AGENT, TOGETHER WITH PACLITAXEL AND / OR CARBOPLATIN, IN A BINARY COMBINATION OR WITH THE THREE COMPONENTS SIMULTANEOUSLY. THE INVENTION ALSO INCLUDES PHARMACOLOGICALLY EFFECTIVE FORMULATIONS, TREATMENTS, IN ADDITION TO THE PRESENTATION IN AN ACETIDINALINE DOSAGE COMPARTMENT AND IN ANOTHER COMPARTMENT A CARBOPLATIN DOSAGE COMPARTMENT AND / OR ANOTHER PACL DOSAGE COMPARTMENT. A COMBINATION OF ANTINEOPLASIC AGENTS THAT INCLUDE AN ANTIBODY AMOUNT OF ACETIDINALINE AND AN ANTIBODY AMOUNT OF PACLITAXEL AND / OR CARBOPLATIN. ACETILDINALINE IN COMBINATION WITH PACLITAXEL AND / OR CARBOPLATIN IS SYNERGISTIC TO TREAT CANCER.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16488999P | 1999-11-10 | 1999-11-10 | |
| US22256100P | 2000-08-03 | 2000-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000194A true GT200000194A (en) | 2002-05-03 |
Family
ID=26860956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000194A GT200000194A (en) | 1999-11-10 | 2000-11-09 | COMBINATION CHEMOTHERAPY. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1229916A2 (en) |
| JP (1) | JP2003513912A (en) |
| KR (1) | KR20020060226A (en) |
| CN (1) | CN1387438A (en) |
| AR (1) | AR026400A1 (en) |
| AU (1) | AU1583201A (en) |
| CA (1) | CA2386876A1 (en) |
| GT (1) | GT200000194A (en) |
| HU (1) | HUP0203153A3 (en) |
| IL (1) | IL149363A0 (en) |
| NZ (1) | NZ518668A (en) |
| PA (1) | PA8506201A1 (en) |
| PE (1) | PE20011028A1 (en) |
| PL (1) | PL355170A1 (en) |
| SV (1) | SV2001000212A (en) |
| UY (1) | UY26431A1 (en) |
| WO (1) | WO2001034131A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022216A3 (en) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Compound chemotherapy |
| PE20050206A1 (en) * | 2003-05-26 | 2005-03-26 | Schering Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE |
| EP1696898B1 (en) * | 2003-12-02 | 2015-11-18 | The Ohio State University Research Foundation | Zn 2+ -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| CN101014365B (en) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| PL2415382T3 (en) | 2010-08-06 | 2013-02-28 | Electrolux Home Products Corp Nv | Table top dishwasher |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
| WO2025026925A1 (en) | 2023-07-28 | 2025-02-06 | Ospedale San Raffaele S.R.L. | Gtf2i inhibitors and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
-
2000
- 2000-11-03 JP JP2001536131A patent/JP2003513912A/en active Pending
- 2000-11-03 CN CN00815470A patent/CN1387438A/en active Pending
- 2000-11-03 HU HU0203153A patent/HUP0203153A3/en unknown
- 2000-11-03 EP EP00978360A patent/EP1229916A2/en not_active Withdrawn
- 2000-11-03 KR KR1020027005970A patent/KR20020060226A/en not_active Withdrawn
- 2000-11-03 IL IL14936300A patent/IL149363A0/en unknown
- 2000-11-03 PL PL00355170A patent/PL355170A1/en not_active Application Discontinuation
- 2000-11-03 NZ NZ518668A patent/NZ518668A/en unknown
- 2000-11-03 AU AU15832/01A patent/AU1583201A/en not_active Abandoned
- 2000-11-03 CA CA002386876A patent/CA2386876A1/en not_active Abandoned
- 2000-11-03 WO PCT/US2000/030377 patent/WO2001034131A2/en not_active Ceased
- 2000-11-07 SV SV2000000212A patent/SV2001000212A/en not_active Application Discontinuation
- 2000-11-09 AR ARP000105899A patent/AR026400A1/en unknown
- 2000-11-09 UY UY26431A patent/UY26431A1/en not_active Application Discontinuation
- 2000-11-09 PA PA20008506201A patent/PA8506201A1/en unknown
- 2000-11-09 GT GT200000194A patent/GT200000194A/en unknown
- 2000-11-09 PE PE2000001196A patent/PE20011028A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PA8506201A1 (en) | 2002-12-11 |
| WO2001034131A2 (en) | 2001-05-17 |
| HUP0203153A3 (en) | 2005-01-28 |
| PE20011028A1 (en) | 2001-10-12 |
| SV2001000212A (en) | 2001-10-25 |
| NZ518668A (en) | 2004-04-30 |
| CA2386876A1 (en) | 2001-05-17 |
| WO2001034131A3 (en) | 2002-05-10 |
| PL355170A1 (en) | 2004-04-05 |
| KR20020060226A (en) | 2002-07-16 |
| IL149363A0 (en) | 2002-11-10 |
| AR026400A1 (en) | 2003-02-12 |
| HUP0203153A2 (en) | 2003-01-28 |
| JP2003513912A (en) | 2003-04-15 |
| EP1229916A2 (en) | 2002-08-14 |
| CN1387438A (en) | 2002-12-25 |
| UY26431A1 (en) | 2000-12-29 |
| AU1583201A (en) | 2001-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28213A1 (en) | NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS. | |
| UY27943A1 (en) | COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS | |
| CL2008002224A1 (en) | Pharmaceutical composition comprising a) a compound selected from paclitaxel, docetaxel, ispinesib, thiazoloquinoline, among others, and b) aurora kinase inhibitor compounds selected from imidazopyrazine derivatives; use of combination and composition to treat cancer. | |
| CR8181A (en) | USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER | |
| DOP2012000290A (en) | 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH ANTI-TUMOR AGENTS FOR USE IN THE TREATMENT OF CANCER UTERO AND CANCER DE OVARIO | |
| ATE538103T1 (en) | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | |
| AR048819A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| UY28287A1 (en) | COMBINATIONS FOR THE TREATMENT OF DISEASES THAT IMPACT CELLULAR PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | |
| BRPI0612845A8 (en) | compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| AR054094A1 (en) | CANCER TREATMENTS | |
| AR048502A1 (en) | ANTI-CANCER COMPOUND THERAPEUTIC SYNERGY | |
| CR7899A (en) | PROTEIN QUINASA INHIBITING TRICICLIC COMPOUNDS TO IMPROVE THE EFFECTIVENESS OF ANTIENOPLASTIC AGENTS AND DERIVATIVES OF DIAZENPAMDIONILO AS QUINASE INHIBITORS | |
| GT200000194A (en) | COMBINATION CHEMOTHERAPY. | |
| BRPI0607809A2 (en) | use of a composition comprising nanoparticles, composition and kit | |
| CO6300964A2 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTIGLIPICAN ANTIBODY 3 | |
| MX340724B (en) | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER. | |
| AR023616A1 (en) | COMBINED PREPARATIONS UNDERSTANDING ANTHRACICLINE DERIVATIVES | |
| AR056801A1 (en) | ANTI-PROLIFERATIVE COMBINED THERAPY WITH CERTAIN PLATINUM-BASED CHEMOTHERAPEUTIC AGENTS AND EGFR INHIBITORS OR PYRIMIDINE ANALOGS | |
| AR040792A1 (en) | THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOPLASIC THERAPIES | |
| ES2172171T3 (en) | MEDICINAL PRODUCT, CONTAINING YOHIMBINE AND ARGININE, FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS. | |
| ATE509630T1 (en) | PANCREAS CANCER TREATMENT WITH NA+/K+-ATPASE INHIBITORS | |
| PE20220250A1 (en) | USE OF DOCETAXEL IN THE TREATMENT OF CANCER THROUGH CONTROL OF MAXIMUM LEVELS IN PLASMA | |
| BRPI0511475A (en) | combination, pharmaceutical composition, use of a combination, and method for treating cancer | |
| EP1691801A4 (en) | SYNERGISTIC ANTICANCER COMPOSITIONS |